First patients are vaccinated in IMPRINT*, immatics' pivotal Phase III trial with IMA901 in patients with renal cell carcinoma (RCC)
immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active agai…